Market News / Story
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
TMX Newsfile ·
TMX Newsfile reports: Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical…